Lasse Meyer, Hartland W. Jackson, Nils Eling, Shan Zhao, Genki Usui, Haithem Dakhli, Peter Schraml, Susanne Dettwiler, Constanze Elfgen, Zsuzsanna Varga, Holger Moch, Natalie de Souza, Bernd Bodenmiller
{"title":"基于基底腔肿瘤细胞和肿瘤空间结构的乳腺癌分层系统","authors":"Lasse Meyer, Hartland W. Jackson, Nils Eling, Shan Zhao, Genki Usui, Haithem Dakhli, Peter Schraml, Susanne Dettwiler, Constanze Elfgen, Zsuzsanna Varga, Holger Moch, Natalie de Souza, Bernd Bodenmiller","doi":"10.1016/j.ccell.2025.06.019","DOIUrl":null,"url":null,"abstract":"Rapid recurrence is common in triple-negative breast cancer (TNBC). To better understand drivers of recurrence, we use imaging mass cytometry to characterize the tumor phenotype landscapes of 215 TNBC patients. We observe high intertumor heterogeneity with eleven tumor cell phenotypes, each of which dominates in an individual patient, and identify a tumor cell phenotype with reduced basoluminal lineage fidelity and stem-like traits that is correlated with rapid disease recurrence. Scoring of tumor-CD8<sup>+</sup> T cell interactions identifies patients with inflamed tumors and high HLADR expression. We combine these features in multi-omics analyses of 8 cohorts with 3737 patients across all molecular subtypes to propose five prognostic breast cancer subtypes distinguished by tumor cytokeratin expression profiles and CD8<sup>+</sup> T cell spatial patterns. This stratification scheme has direct clinical implications: inflamed tumors show good prognosis and high immunotherapy response rates, whereas patients dominated by basoluminal tumor cells have poor prognosis.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"2 1","pages":""},"PeriodicalIF":48.8000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture\",\"authors\":\"Lasse Meyer, Hartland W. Jackson, Nils Eling, Shan Zhao, Genki Usui, Haithem Dakhli, Peter Schraml, Susanne Dettwiler, Constanze Elfgen, Zsuzsanna Varga, Holger Moch, Natalie de Souza, Bernd Bodenmiller\",\"doi\":\"10.1016/j.ccell.2025.06.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rapid recurrence is common in triple-negative breast cancer (TNBC). To better understand drivers of recurrence, we use imaging mass cytometry to characterize the tumor phenotype landscapes of 215 TNBC patients. We observe high intertumor heterogeneity with eleven tumor cell phenotypes, each of which dominates in an individual patient, and identify a tumor cell phenotype with reduced basoluminal lineage fidelity and stem-like traits that is correlated with rapid disease recurrence. Scoring of tumor-CD8<sup>+</sup> T cell interactions identifies patients with inflamed tumors and high HLADR expression. We combine these features in multi-omics analyses of 8 cohorts with 3737 patients across all molecular subtypes to propose five prognostic breast cancer subtypes distinguished by tumor cytokeratin expression profiles and CD8<sup>+</sup> T cell spatial patterns. This stratification scheme has direct clinical implications: inflamed tumors show good prognosis and high immunotherapy response rates, whereas patients dominated by basoluminal tumor cells have poor prognosis.\",\"PeriodicalId\":9670,\"journal\":{\"name\":\"Cancer Cell\",\"volume\":\"2 1\",\"pages\":\"\"},\"PeriodicalIF\":48.8000,\"publicationDate\":\"2025-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Cell\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ccell.2025.06.019\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ccell.2025.06.019","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture
Rapid recurrence is common in triple-negative breast cancer (TNBC). To better understand drivers of recurrence, we use imaging mass cytometry to characterize the tumor phenotype landscapes of 215 TNBC patients. We observe high intertumor heterogeneity with eleven tumor cell phenotypes, each of which dominates in an individual patient, and identify a tumor cell phenotype with reduced basoluminal lineage fidelity and stem-like traits that is correlated with rapid disease recurrence. Scoring of tumor-CD8+ T cell interactions identifies patients with inflamed tumors and high HLADR expression. We combine these features in multi-omics analyses of 8 cohorts with 3737 patients across all molecular subtypes to propose five prognostic breast cancer subtypes distinguished by tumor cytokeratin expression profiles and CD8+ T cell spatial patterns. This stratification scheme has direct clinical implications: inflamed tumors show good prognosis and high immunotherapy response rates, whereas patients dominated by basoluminal tumor cells have poor prognosis.
期刊介绍:
Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows:
Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers.
Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice.
Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers.
Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies.
Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.